Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Eight subjects at T0, 12 subjects at T1 and 11 subjects at T2 were also receiving cholecalciferol supplementation at the dose of 1000 UI per day.Comparison of clinical and metabolic markers over time in the whole cohortMetabolic markersT0T1T2pvalueChronological age (years)9.3 ± 4.89.7 ± 4.710.2 ± 4.7: Weight (SDS)0.8 ± 1.20.9 ± 1.10.8 ± 1.2n.s.bHeight (SDS)0.04 ± 1.20.05 ± 1.30.03 ± 1.3n.s.bBMI (SDS)0.9 ± 1.01.0 ± 1.10.9 ± 1.1n.s.bSBP (mmHg)107.0 (105∼120)114.5 (102.5 to 120.0)110.5 (105 to 120)n.s.aDBP (mmHg)67.8 ± 11.870.2 ± 13.568.0 ± 12.7n.s.b17-OHP (ng/mL)11.1 (3.0 to 25.1)7.1 (1.8 to 19.9)5.9 (2.0 to 20.0)*0.005aDHEAS (mcg/dL)7.2 (1.2 to 20.7)3.0 (0.2 to 16.3)9.9 (1.9 to 25.2)n.saΔ4-Androstendione (ng/mL)0.9 (0.3 to 2.5)0.3 (0.3 to 1.1)0.5 (0.3 to 1.5)*0.014aACTH (pg/mL)58.5 (16.0 to 195.5)57.7 (14.6 to 187.5)35.0 (16.0 to 116.2)n.s.aCa/Cr ratio0.08 (0.05 to 0.16)0.11 (0.05 to 0.17)0.09 (0.06 to 0.18)n.s.a25-OH VitD (ng/mL)22.0 (17.7 to 25.0)24.0 (17.4 to 28.0)26.0 (22.7 to 30.9)*0.004aPTH (pg/mL)27.2 (23.0 to 34.5)28.0 (24.3 to 40.9)25.2 (17.2 to 38.6)n.s.aCa (mg/dl)9.8 ± 0.59.9 ± 0.49.6 ± 0.4n.s.bP (mg/dl)4.8 ± (4.2 to 5.2)4.6 (4.1 to 5.3)4.6 (4.2 to 5.0)n.s bNa (mEq/L)139 (138 to 140)139 (138 to 140)139 (138 to 140)n.s.bK (mEq/L)4.5 ± 0.54.4 ± 0.44.4 ± 0.4n.s.b17-OHP 17-hydroxyprogesterone progesterone, DHEAS dehydroepiandrosterone sulfate, ACTH adrenocorticotrophic hormone, Ca/Cr calcium/creatinine ratioData are presented as mean ± SD for normally distributed variables, and median with interquartile range for non-normally distributed variablesaNon-parametric ANOVA on repeated measuresbANOVA on repeated measuresThe superscripts * above to each value indicates statistically significant difference (p < 0.05) in the amount of variable over time
Source: Patient population. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Increased risk of nephrolithiasis: an emerging issue in children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Study design awaiting verification · Endocrine · 2024
Original publication title
Increased risk of nephrolithiasis: an emerging issue in children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
© The Author(s) 2024
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
To investigate the incidence of nephrolithiasis in a cohort of children with congenital adrenal hyperplasia (CAH), and to study if there is an association with the metabolic control of the disease.
Source: PurposeAbstract: What methods does the paper describe?
This study was designed as a multicenter 1 year-prospective study involving 52 subjects (35 males) with confirmed molecular diagnosis of CAH due to 21-hydroxylase deficiency (21-OHD). Each patient was evaluated at three different time-points: T0, T1 (+6 months of follow-up), T2 (+12 months of follow up). At each follow up visit, auxological data were collected, and adrenocorticotrophic hormone (ACTH), 17-hydroxyprogesterone (17-OHP), Δ4-androstenedione, dehydroepiandrosterone sulfate (DHEAS) serum levels, and urinary excretion of creatinine, calcium, oxalate and citrate were assayed. Moreover, a renal ultrasound was performed.
Source: MethodsAbstract: Results
The incidence of nephrolithiasis, assessed by ultrasound was 17.3% at T0, 13.5% at T1 and 11.5% at T2. At T0, one subject showed nephrocalcinosis. In the study population, a statistically significant difference was found for 17-OHP [T0: 11.1 (3.0 to 25.1) ng/mL; T1: 7.1 (1.8 to 19.9) ng/mL; T2: 5.9 (2.0 to 20.0) ng/mL, p < 0.005], and Δ4-androstenedione [T0: 0.9 (0.3 to 2.5) ng/mL; T1: 0.3 (0.3 to 1.1) ng/mL; T2: 0.5 (0.3 to 1.5) ng/mL, p < 0.005] which both decreased over the follow up time. No statistically significant difference among metabolic markers was found in the group of the subjects with nephrolithiasis, even if 17-OHP, DHEAS and Δ4-androstenedione levels showed a tendency towards a reduction from T0 to T2.
Principal component analysis (PCA) was performed to study possible hidden patterns of associations/correlations between variables, and to assess the trend of them during the time. PCA revealed a decrease in the amount of the variables 17-OHP, Δ4-androstenedione, and ACTH that occurred during follow-up, which was also observed in subjects showing nephrolithiasis.
Source: ResultsAbstract: Conclusions
our data demonstrated that children affected with 21-OHD can be at risk of developing nephrolithiasis. Additional studies are needed to clarify the pathogenesis and other possible risk factors for this condition, and to establish if regular screening of kidney ultrasound in these patients can be indicated.
Source: ConclusionsAuthors’ abstract
Purpose
To investigate the incidence of nephrolithiasis in a cohort of children with congenital adrenal hyperplasia (CAH), and to study if there is an association with the metabolic control of the disease.
Methods
This study was designed as a multicenter 1 year-prospective study involving 52 subjects (35 males) with confirmed molecular diagnosis of CAH due to 21-hydroxylase deficiency (21-OHD). Each patient was evaluated at three different time-points: T0, T1 (+6 months of follow-up), T2 (+12 months of follow up). At each follow up visit, auxological data were collected, and adrenocorticotrophic hormone (ACTH), 17-hydroxyprogesterone (17-OHP), Δ4-androstenedione, dehydroepiandrosterone sulfate (DHEAS) serum levels, and urinary excretion of creatinine, calcium, oxalate and citrate were assayed. Moreover, a renal ultrasound was performed.
Results
The incidence of nephrolithiasis, assessed by ultrasound was 17.3% at T0, 13.5% at T1 and 11.5% at T2. At T0, one subject showed nephrocalcinosis. In the study population, a statistically significant difference was found for 17-OHP [T0: 11.1 (3.0 to 25.1) ng/mL; T1: 7.1 (1.8 to 19.9) ng/mL; T2: 5.9 (2.0 to 20.0) ng/mL, p < 0.005], and Δ4-androstenedione [T0: 0.9 (0.3 to 2.5) ng/mL; T1: 0.3 (0.3 to 1.1) ng/mL; T2: 0.5 (0.3 to 1.5) ng/mL, p < 0.005] which both decreased over the follow up time. No statistically significant difference among metabolic markers was found in the group of the subjects with nephrolithiasis, even if 17-OHP, DHEAS and Δ4-androstenedione levels showed a tendency towards a reduction from T0 to T2.
Principal component analysis (PCA) was performed to study possible hidden patterns of associations/correlations between variables, and to assess the trend of them during the time. PCA revealed a decrease in the amount of the variables 17-OHP, Δ4-androstenedione, and ACTH that occurred during follow-up, which was also observed in subjects showing nephrolithiasis.
Conclusions
our data demonstrated that children affected with 21-OHD can be at risk of developing nephrolithiasis. Additional studies are needed to clarify the pathogenesis and other possible risk factors for this condition, and to establish if regular screening of kidney ultrasound in these patients can be indicated.
Publication and source details
Original title: Increased risk of nephrolithiasis: an emerging issue in children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Mariangela Chiarito; Crescenza Lattanzio; Vito D’Ascanio; Donatella Capalbo; Paolo Cavarzere; Anna Grandone; Francesca Aiello; Giorgia Pepe; Malgorzata Wasniewska; Thomas Zoller; Mariacarolina Salerno; Maria Felicia Faienza
Endocrine · 2024
© The Author(s) 2024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T12:31:24.129046+00:00
DOI: 10.1007/s12020-024-03792-6 · PMC11076308